GLP-1 medications are not overnight solutions
US list prices for weight-loss jabs are about $1,000 a month or more, although Novo Nordisk started selling its Wegovy injection at $349 a month to cash payers in November
For patients taking warfarin, physicians typically rely on laboratory tests known as the International Normalized Ratio (INR)
A muscle-preserving weight-loss strategy may include: Medical history review Weight and body-composition goals Nutrition planning Protein guidance Resistance-training recommendations Metabolic lab review Hormone and thyroid considerations when appropriate Medication review GLP-1 education Peptide therapy discussion when medically appropriate Ongoing monitoring and adjustment This type of care is especially important for patients who have: Insulin resistance Prediabetes Type 2 diabetes Menopause-related body-composition changes Low energy Low muscle mass A history of repeated dieting Thyroid concerns High stress Poor sleep Prior weight regain Concerns about rapid weight loss For these patients, a generic weight-loss plan is rarely enough
The 88.8% completion rate through 48 weeks confirms that side effects become manageable for the vast majority of patients
For patients who may not have achieved optimal results with dual agonists, or those with unique comorbidities like advanced non-alcoholic fatty liver disease (NAFLD), the introduction of Retatrutide is not just an incremental improvement, it is a re-evaluation of treatment goals
